MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation Life Science Investing
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+ Biotech Investing
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses Life Science Investing
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update Life Science Investing
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Life Science Investing
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update Life Science Investing
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results Life Science Investing
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update Life Science Investing
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter Life Science Investing
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting Life Science Investing
Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference Life Science Investing
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026Â
